Nonviral delivery of genetic medicine for therapeutic angiogenesis

Advanced Drug Delivery Reviews

Volumn 64, Issue 1, 2012, Pages 40-52

  Park, Hyun Ji ^a   Yang, Fan ^b   Cho, Seung Woo ^a  

^a Yonsei University   (South Korea)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic medicines; High throughput screening; Ischemia; Nonviral delivery; Therapeutic angiogenesis

Indexed keywords

ANGIOGENESIS; CATIONIC POLYMERS; CLINICAL APPLICATION; CLINICAL TRIAL; COMBINATORIAL LIBRARY; CURRENT TECHNOLOGY; DELIVERY SYSTEMS; DELIVERY VEHICLE; FUTURE STRATEGY; HIGH-THROUGHPUT SCREENING; ISCHEMIA; NON-VIRAL GENE DELIVERY; NONVIRAL; NONVIRAL GENE THERAPY; THERAPEUTIC ANGIOGENESIS; THERAPEUTIC EFFICACY;

BIOLOGICAL MATERIALS; DIAGNOSIS; GENE THERAPY; GENE TRANSFER; SCAFFOLDS (BIOLOGY); STEM CELLS;

FUNCTIONAL POLYMERS;

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 1; NETRIN 1; PLACEBO; PLASMID VECTOR; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN C;

ANGIOGENESIS; BUERGER DISEASE; COMBINATORIAL LIBRARY; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GENETIC ENGINEERING; HEART INFARCTION; HIGH THROUGHPUT SCREENING; HUMAN; LIMB ISCHEMIA; LIPOSOMAL DELIVERY; NEOINTIMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; STEM CELL GENE THERAPY;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS;

EID: 84858442652     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.09.005     Document Type: Review

References (150)

1. Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal K., Ford E., Furie K., Go A., Greenlund K., Haase N., Hailpern S., Ho M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M., Meigs J., Mozaffarian D., Nichol G., O'Donnell C., Roger V., Rosamond W., Sacco R., Sorlie P., Stafford R., Steinberger J., Thom T., Wasserthiel-Smoller S., Wong N., Wylie-Rosett J., Hong Y. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21-e181.
2. Kusano K.F., Pola R., Murayama T., Curry C., Kawamoto A., Iwakura A., Shintani S., Ii M., Asai J., Tkebuchava T., Thorne T., Takenaka H., Aikawa R., Goukassian D., von Samson P., Hamada H., Yoon Y.S., Silver M., Eaton E., Ma H., Heyd L., Kearney M., Munger W., Porter J.A., Kishore R., Losordo D.W. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat. Med. 2005, 11:1197-1204.
3. Hirsch A.T., Criqui M.H., Treat-Jacobson D., Regensteiner J.G., Creager M.A., Olin J.W., Krook S.H., Hunninghake D.B., Comerota A.J., Walsh M.E., McDermott M.M., Hiatt W.R. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286:1317-1324.
4. Nikol S., Baumgartner I., Van Belle E., Diehm C., Visona A., Capogrossi M.C., Ferreira-Maldent N., Gallino A., Wyatt M.G., Wijesinghe L.D., Fusari M., Stephan D., Emmerich J., Pompilio G., Vermassen F., Pham E., Grek V., Coleman M., Meyer F. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 2008, 16:972-978.
5. Bertele V., Roncaglioni M.C., Pangrazzi J., Terzian E., Tognoni E.G. Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. Eur. J. Vasc. Endovasc. Surg. 1999, 18:401-410.
6. Brewster L.P., Brey E.M., Greisler H.P. Cardiovascular gene delivery: the good road is awaiting. Adv. Drug Deliv. Rev. 2006, 58:604-629.
7. Whitlock P.R., Hackett N.R., Leopold P.L., Rosengart T.K., Crystal R.G. Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol. Ther. 2004, 9:67-75.
8. Rutanen J., Rissanen T.T., Markkanen J.E., Gruchala M., Silvennoinen P., Kivela A., Hedman A., Hedman M., Heikura T., Orden M.R., Stacker S.A., Achen M.G., Hartikainen J., Yla-Herttuala S. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004, 109:1029-1035.
9. Lazarous D.F., Shou M., Stiber J.A., Hodge E., Thirumurti V., Goncalves L., Unger E.F. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc. Res. 1999, 44:294-302.
10. Patel S.R., Lee L.Y., Mack C.A., Polce D.R., El-Sawy T., Hackett N.R., Ilercil A., Jones E.C., Hahn R.T., Isom O.W., Rosengart T.K., Crystal R.G. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. Hum. Gene Ther. 1999, 10:1331-1348.
11. Garcia-Martinez C., Opolon P., Trochon V., Chianale C., Musset K., Lu H., Abitbol M., Perricaudet M., Ragot T. Angiogenesis induced in muscle by a recombinant adenovirus expressing functional isoforms of basic fibroblast growth factor. Gene Ther. 1999, 6:1210-1221.
12. Ueda H., Sawa Y., Matsumoto K., Kitagawa-Sakakida S., Kawahira Y., Nakamura T., Kaneda Y., Matsuda H. Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann. Thorac. Surg. 1999, 67:1726-1731.
13. Rosengart T.K., Lee L.Y., Patel S.R., Sanborn T.A., Parikh M., Bergman G.W., Hachamovitch R., Szulc M., Kligfield P.D., Okin P.M., Hahn R.T., Devereux R.B., Post M.R., Hackett N.R., Foster T., Grasso T.M., Lesser M.L., Isom O.W., Crystal R.G. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999, 100:468-474.
14. Giordano F.J., Ping P., McKirnan M.D., Nozaki S., DeMaria A.N., Dillmann W.H., Mathieu-Costello O., Hammond H.K. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. 1996, 2:534-539.
15. Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2007 - an update. J. Gene Med. 2007, 9:833-842.
16. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4:346-358.
17. Hughes V. Therapy on trial. Nat. Med. 2007, 13:1008-1009.
18. Hollon T. Researchers and regulators reflect on first gene therapy death. Nat. Med. 2000, 6:6.
19. Check E. Gene therapy put on hold as third child develops cancer. Nature 2005, 433:561.
20. Green J.J., Langer R., Anderson D.G. A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc. Chem. Res. 2008, 41:749-759.
21. Putnam D. Polymers for gene delivery across length scales. Nat. Mater. 2006, 5:439-451.
22. Yockman J.W., Kastenmeier A., Erickson H.M., Brumbach J.G., Whitten M.G., Albanil A., Li D.Y., Kim S.W., Bull D.A. Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction. J. Control Release 2008, 132:260-266.
23. Tsurumi Y., Takeshita S., Chen D., Kearney M., Rossow S.T., Passeri J., Horowitz J.R., Symes J.F., Isner J.M. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996, 94:3281-3290.
24. Tio R.A., Tkebuchava T., Scheuermann T.H., Lebherz C., Magner M., Kearny M., Esakof D.D., Isner J.M., Symes J.F. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum. Gene Ther. 1999, 10:2953-2960.
25. Heilmann C., von Samson P., Schlegel K., Attmann T., von Specht B.U., Beyersdorf F., Lutter G. Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2. Eur. J. Cardiothorac. Surg. 2002, 22:957-964.
26. Taniyama Y., Morishita R., Aoki M., Nakagami H., Yamamoto K., Yamazaki K., Matsumoto K., Nakamura T., Kaneda Y., Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 2001, 8:181-189.
27. Rabinovsky E.D., Draghia-Akli R. Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis. Mol. Ther. 2004, 9:46-55.
28. Shyu K.G., Manor O., Magner M., Yancopoulos G.D., Isner J.M. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 1998, 98:2081-2087.
29. Qian H.S., Liu P., Huw L.Y., Orme A., Halks-Miller M., Hill S.M., Jin F., Kretschmer P., Blasko E., Cashion L., Szymanski P., Vergona R., Harkins R., Yu J., Sessa W.C., Dole W.P., Rubanyi G.M., Kauser K. Effective treatment of vascular endothelial growth factor refractory hindlimb ischemia by a mutant endothelial nitric oxide synthase gene. Gene Ther. 2006, 13:1342-1350.
30. Namba T., Koike H., Murakami K., Aoki M., Makino H., Hashiya N., Ogihara T., Kaneda Y., Kohno M., Morishita R. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 2003, 108:2250-2257.
31. Wilson B.D., Ii M., Park K.W., Suli A., Sorensen L.K., Larrieu-Lahargue F., Urness L.D., Suh W., Asai J., Kock G.A., Thorne T., Silver M., Thomas K.R., Chien C.B., Losordo D.W., Li D.Y. Netrins promote developmental and therapeutic angiogenesis. Science 2006, 313:640-644.
32. Sugano M., Tsuchida K., Makino N. Intramuscular gene transfer of soluble tumor necrosis factor-alpha receptor 1 activates vascular endothelial growth factor receptor and accelerates angiogenesis in a rat model of hindlimb ischemia. Circulation 2004, 109:797-802.
33. Sugano M., Tsuchida K., Hata T., Makino N. In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats. FASEB J. 2004, 18:911-913.
34. Hiasa K., Ishibashi M., Ohtani K., Inoue S., Zhao Q., Kitamoto S., Sata M., Ichiki T., Takeshita A., Egashira K. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004, 109:2454-2461.
35. Herweijer H., Wolff J.A. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther. 2003, 10:453-458.
36. Brito L., Little S., Langer R., Amiji M. Poly(beta-amino ester) and cationic phospholipid-based lipopolyplexes for gene delivery and transfection in human aortic endothelial and smooth muscle cells. Biomacromolecules 2008, 9:1179-1187.
37. Xu P., Li S.Y., Li Q., Ren J., Van Kirk E.A., Murdoch W.J., Radosz M., Shen Y. Biodegradable cationic polyester as an efficient carrier for gene delivery to neonatal cardiomyocytes. Biotechnol. Bioeng. 2006, 95:893-903.
38. Nam H.Y., Nam K., Hahn H.J., Kim B.H., Lim H.J., Kim H.J., Choi J.S., Park J.S. Biodegradable PAMAM ester for enhanced transfection efficiency with low cytotoxicity. Biomaterials 2009, 30:665-673.
39. Zaric V., Weltin D., Erbacher P., Remy J.S., Behr J.P., Stephan D. Effective polyethylenimine-mediated gene transfer into human endothelial cells. J. Gene Med. 2004, 6:176-184.
40. Ishikawa A., Zhou Y.M., Kambe N., Nakayama Y. Enhancement of star vector-based gene delivery to endothelial cells by addition of RGD-peptide. Bioconjug. Chem. 2008, 19:558-561.
41. Yu L., Nielsen M., Han S.O., Wan Kim S. TerplexDNA gene carrier system targeting artery wall cells. J. Control. Release 2001, 72:179-189.
42. Putnam D., Gentry C.A., Pack D.W., Langer R. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1200-1205.
43. Jeon O., Yang H.S., Lee T.J., Kim B.S. Heparin-conjugated polyethylenimine for gene delivery. J. Control. Release 2008, 132:236-242.
44. Du Y.J., Brash J.L., McClung G., Berry L.R., Klement P., Chan A.K. Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex. J. Biomed. Mater. Res. A 2007, 80:216-225.
45. Han D.K., Jeong S.Y., Kim Y.H. Evaluation of blood compatibility of PEO grafted and heparin immobilized polyurethanes. J. Biomed. Mater. Res. 1989, 23:211-228.
46. Lee M., Rentz J., Han S.O., Bull D.A., Kim S.W. Water-soluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther. 2003, 10:585-593.
47. Lee M., Rentz J., Bikram M., Han S., Bull D.A., Kim S.W. Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther. 2003, 10:1535-1542.
48. Yockman J.W., Choi D., Whitten M.G., Chang C.W., Kastenmeier A., Erickson H., Albanil A., Lee M., Kim S.W., Bull D.A. Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. Gene Ther. 2009, 16:127-135.
49. Yockman J.W., Maheshwari A., Han S.O., Kim S.W. Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes. J. Control. Release 2003, 87:177-186.
50. Zhang J.X., Zalipsky S., Mullah N., Pechar M., Allen T.M. Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol. Res. 2004, 49:185-198.
51. Golda A., Pelisek J., Klocke R., Engelmann M.G., Rolland P.H., Mekkaoui C., Nikol S. Small poly-l-lysines improve cationic lipid-mediated gene transfer in vascular cells in vitro and in vivo. J. Vasc. Res. 2007, 44:273-282.
52. Anwer K., Kao G., Rolland A., Driessen W.H., Sullivan S.M. Peptide-mediated gene transfer of cationic lipid/plasmid DNA complexes to endothelial cells. J. Drug Target. 2004, 12:215-221.
53. Driessen W.H., Fujii N., Tamamura H., Sullivan S.M. Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells. Mol. Ther. 2008, 16:516-524.
54. Lampela P., Elomaa M., Ruponen M., Urtti A., Mannisto P.T., Raasmaja A. Different synergistic roles of small polyethylenimine and Dosper in gene delivery. J. Control. Release 2003, 88:173-183.
55. Eastman S.J., Siegel C., Tousignant J., Smith A.E., Cheng S.H., Scheule R.K. Biophysical characterization of cationic lipid: DNA complexes. Biochim. Biophys. Acta 1997, 1325:41-62.
56. Zelphati O., Szoka F.C. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11493-11498.
57. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35:5616-5623.
58. Faneca H., Simoes S., de Lima M.C. Evaluation of lipid-based reagents to mediate intracellular gene delivery. Biochim. Biophys. Acta 2002, 1567:23-33.
59. Leong-Poi H., Kuliszewski M.A., Lekas M., Sibbald M., Teichert-Kuliszewska K., Klibanov A.L., Stewart D.J., Lindner J.R. Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. Circ. Res. 2007, 101:295-303.
60. Bekeredjian R., Chen S., Frenkel P.A., Grayburn P.A., Shohet R.V. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation 2003, 108:1022-1026.
61. Torchilin V.P., Levchenko T.S., Rammohan R., Volodina N., Papahadjopoulos-Sternberg B., D'Souza G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1972-1977.
62. Ko Y.T., Hartner W.C., Kale A., Torchilin V.P. Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther. 2009, 16:52-59.
63. Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 2005, 4:581-593.
64. Yang N., Ye Z., Li F., Mahato R.I. HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells. Bioconjug. Chem. 2009, 20:213-221.
65. Storrie H., Mooney D.J. Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Adv. Drug Deliv. Rev. 2006, 58:500-514.
66. Gounis M.J., Spiga M.G., Graham R.M., Wilson A., Haliko S., Lieber B.B., Wakhloo A.K., Webster K.A. Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther. 2005, 12:762-771.
67. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
68. Jang J.H., Rives C.B., Shea L.D. Plasmid delivery in vivo from porous tissue-engineering scaffolds: transgene expression and cellular transfection. Mol. Ther. 2005, 12:475-483.
69. Mao Z., Shi H., Guo R., Ma L., Gao C., Han C., Shen J. Enhanced angiogenesis of porous collagen scaffolds by incorporation of TMC/DNA complexes encoding vascular endothelial growth factor. Acta Biomater. 2009, 5:2983-2994.
70. Doukas J., Blease K., Craig D., Ma C., Chandler L.A., Sosnowski B.A., Pierce G.F. Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle. Mol. Ther. 2002, 5:517-527.
71. Shea L.D., Smiley E., Bonadio J., Mooney D.J. DNA delivery from polymer matrices for tissue engineering. Nat. Biotechnol. 1999, 17:551-554.
72. Kasahara H., Tanaka E., Fukuyama N., Sato E., Sakamoto H., Tabata Y., Ando K., Iseki H., Shinozaki Y., Kimura K., Kuwabara E., Koide S., Nakazawa H., Mori H. Biodegradable gelatin hydrogel potentiates the angiogenic effect of fibroblast growth factor 4 plasmid in rabbit hindlimb ischemia. J. Am. Coll. Cardiol. 2003, 41:1056-1062.
73. Kong H.J., Kim E.S., Huang Y.C., Mooney D.J. Design of biodegradable hydrogel for the local and sustained delivery of angiogenic plasmid DNA. Pharm. Res. 2008, 25:1230-1238.
74. Trentin D., Hall H., Wechsler S., Hubbell J.A. Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2506-2511.
75. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002, 16:1217-1226.
76. Kang S.W., Lim H.W., Seo S.W., Jeon O., Lee M., Kim B.S. Nanosphere-mediated delivery of vascular endothelial growth factor gene for therapeutic angiogenesis in mouse ischemic limbs. Biomaterials 2008, 29:1109-1117.
77. Yi F., Wu H., Jia G.L. Formulation and characterization of poly (D, L-lactide-co-glycolide) nanoparticle containing vascular endothelial growth factor for gene delivery. J. Clin. Pharm. Ther. 2006, 31:43-48.
78. Klugherz B.D., Jones P.L., Cui X., Chen W., Meneveau N.F., DeFelice S., Connolly J., Wilensky R.L., Levy R.J. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat. Biotechnol. 2000, 18:1181-1184.
79. Perlstein I., Connolly J.M., Cui X., Song C., Li Q., Jones P.L., Lu Z., DeFelice S., Klugherz B., Wilensky R., Levy R.J. DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther. 2003, 10:1420-1428.
80. Walter D.H., Cejna M., Diaz-Sandoval L., Willis S., Kirkwood L., Stratford P.W., Tietz A.B., Kirchmair R., Silver M., Curry C., Wecker A., Yoon Y.S., Heidenreich R., Hanley A., Kearney M., Tio F.O., Kuenzler P., Isner J.M., Losordo D.W. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 2004, 110:36-45.
81. Egashira K., Nakano K., Ohtani K., Funakoshi K., Zhao G., Ihara Y., Koga J., Kimura S., Tominaga R., Sunagawa K. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2563-2568.
82. Zhong H., Matsui O., Xu K., Ogi T., Sanada J., Okamoto Y., Tabata Y., Takuwa Y. Gene transduction into aortic wall using plasmid-loaded cationized gelatin hydrogel-coated polyester stent graft. J. Vasc. Surg. 2009, 50:1433-1443.
83. Takemoto Y., Kawata H., Soeda T., Imagawa K., Somekawa S., Takeda Y., Uemura S., Matsumoto M., Fujimura Y., Jo J., Kimura Y., Tabata Y., Saito Y. Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:857-862.
84. Ou M., Kim T.I., Yockman J.W., Borden B.A., Bull D.A., Kim S.W. Polymer transfected primary myoblasts mediated efficient gene expression and angiogenic proliferation. J. Control. Release 2010, 142:61-69.
85. Neuhuber B., Huang D.I., Daniels M.P., Torgan C.E. High efficiency transfection of primary skeletal muscle cells with lipid-based reagents. Muscle Nerve 2002, 26:136-140.
86. Lu Q.L., Bou-Gharios G., Partridge T.A. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther. 2003, 10:131-142.
87. Helbling-Leclerc A., Scherman D., Wils P. Cellular uptake of cationic lipid/DNA complexes by cultured myoblasts and myotubes. Biochim. Biophys. Acta 1999, 1418:165-175.
88. Lemieux P., Guerin N., Paradis G., Proulx R., Chistyakova L., Kabanov A., Alakhov V. A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle. Gene Ther. 2000, 7:986-991.
89. Mumper R.J., Duguid J.G., Anwer K., Barron M.K., Nitta H., Rolland A.P. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle. Pharm. Res. 1996, 13:701-709.
90. Ruponen M., Ronkko S., Honkakoski P., Pelkonen J., Tammi M., Urtti A. Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. J. Biol. Chem. 2001, 276:33875-33880.
91. Yau T.M., Kim C., Li G., Zhang Y., Weisel R.D., Li R.K. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation 2005, 112:I123-I128.
92. Yau T.M., Kim C., Li G., Zhang Y., Fazel S., Spiegelstein D., Weisel R.D., Li R.K. Enhanced angiogenesis with multimodal cell-based gene therapy. Ann. Thorac. Surg. 2007, 83:1110-1119.
93. Yang J., Zhou W., Zheng W., Ma Y., Lin L., Tang T., Liu J., Yu J., Zhou X., Hu J. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 2007, 107:17-29.
94. Ye L., Haider H., Tan R., Su L., Law P.K., Zhang W., Sim E.K. Angiomyogenesis using liposome based vascular endothelial growth factor-165 transfection with skeletal myoblast for cardiac repair. Biomaterials 2008, 29:2125-2137.
95. Ye L., Haider H., Tan R., Toh W., Law P.K., Tan W., Su L., Zhang W., Ge R., Zhang Y., Lim Y., Sim E.K. Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation 2007, 116:I113-I120.
96. Zhang M., Mal N., Kiedrowski M., Chacko M., Askari A.T., Popovic Z.B., Koc O.N., Penn M.S. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J. 2007, 21:3197-3207.
97. Elmadbouh I., Haider H., Jiang S., Idris N.M., Lu G., Ashraf M. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J. Mol. Cell. Cardiol. 2007, 42:792-803.
98. Askari A.T., Unzek S., Popovic Z.B., Goldman C.K., Forudi F., Kiedrowski M., Rovner A., Ellis S.G., Thomas J.D., DiCorleto P.E., Topol E.J., Penn M.S. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
99. Li W., Ma N., Ong L.L., Nesselmann C., Klopsch C., Ladilov Y., Furlani D., Piechaczek C., Moebius J.M., Lutzow K., Lendlein A., Stamm C., Li R.K., Steinhoff G. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 2007, 25:2118-2127.
100. Tang Y.L., Tang Y., Zhang Y.C., Qian K., Shen L., Phillips M.I. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J. Am. Coll. Cardiol. 2005, 46:1339-1350.
101. Jo J., Nagaya N., Miyahara Y., Kataoka M., Harada-Shiba M., Kangawa K., Tabata Y. Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: benefit of a novel nonviral vector, cationized dextran. Tissue Eng. 2007, 13:313-322.
102. Song H., Chang W., Lim S., Seo H.S., Shim C.Y., Park S., Yoo K.J., Kim B.S., Min B.H., Lee H., Jang Y., Chung N., Hwang K.C. Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells. Stem Cells 2007, 25:1431-1438.
103. Schuldiner M., Itskovitz-Eldor J., Benvenisty N. Selective ablation of human embryonic stem cells expressing a "suicide" gene. Stem Cells 2003, 21:257-265.
104. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
105. Sugano M., Tsuchida K., Hata T., Makino N. RNA interference targeting SHP-1 attenuates myocardial infarction in rats. FASEB J. 2005, 19:2054-2056.
106. Sugano M., Tsuchida K., Maeda T., Makino N. SiRNA targeting SHP-1 accelerates angiogenesis in a rat model of hindlimb ischemia. Atherosclerosis 2007, 191:33-39.
107. Guo D.Q., Wu L.W., Dunbar J.D., Ozes O.N., Mayo L.D., Kessler K.M., Gustin J.A., Baerwald M.R., Jaffe E.A., Warren R.S., Donner D.B. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J. Biol. Chem. 2000, 275:11216-11221.
108. Cho S.W., Hartle L., Son S.M., Yang F., Goldberg M., Xu Q., Langer R., Anderson D.G. Delivery of small interfering RNA for inhibition of endothelial cell apoptosis by hypoxia and serum deprivation. Biochem. Biophys. Res. Commun. 2008, 376:158-163.
109. Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A., Burchfield J., Fox H., Doebele C., Ohtani K., Chavakis E., Potente M., Tjwa M., Urbich C., Zeiher A.M., Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324:1710-1713.
110. Huang M., Chan D.A., Jia F., Xie X., Li Z., Hoyt G., Robbins R.C., Chen X., Giaccia A.J., Wu J.C. Short hairpin RNA interference therapy for ischemic heart disease. Circulation 2008, 118:S226-S233.
111. Wu S., Nishiyama N., Kano M.R., Morishita Y., Miyazono K., Itaka K., Chung U.I., Kataoka K. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. Mol. Ther. 2008, 16:1227-1234.
112. Natarajan R., Salloum F.N., Fisher B.J., Kukreja R.C., Fowler A.A. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ. Res. 2006, 98:133-140.
113. Natarajan R., Salloum F.N., Fisher B.J., Ownby E.D., Kukreja R.C., Fowler A.A. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H1571-H1580.
114. Isner J.M., Pieczek A., Schainfeld R., Blair R., Haley L., Asahara T., Rosenfield K., Razvi S., Walsh K., Symes J.F. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996, 348:370-374.
115. Baumgartner I., Pieczek A., Manor O., Blair R., Kearney M., Walsh K., Isner J.M. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998, 97:1114-1123.
116. Kim H.J., Jang S.Y., Park J.I., Byun J., Kim D.I., Do Y.S., Kim J.M., Kim S., Kim B.M., Kim W.B., Kim D.K. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp. Mol. Med. 2004, 36:336-344.
117. Losordo D.W., Vale P.R., Symes J.F., Dunnington C.H., Esakof D.D., Maysky M., Ashare A.B., Lathi K., Isner J.M. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998, 98:2800-2804.
118. Losordo D.W., Vale P.R., Hendel R.C., Milliken C.E., Fortuin F.D., Cummings N., Schatz R.A., Asahara T., Isner J.M., Kuntz R.E. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002, 105:2012-2018.
119. Fortuin F.D., Vale P., Losordo D.W., Symes J., DeLaria G.A., Tyner J.J., Schaer G.L., March R., Snell R.J., Henry T.D., Van Camp J., Lopez J.J., Richenbacher W., Isner J.M., Schatz R.A. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am. J. Cardiol. 2003, 92:436-439.
120. Reilly J.P., Grise M.A., Fortuin F.D., Vale P.R., Schaer G.L., Lopez J., JR V.A.N.C., Henry T., Richenbacher W.E., Losordo D.W., Schatz R.A., Isner J.M. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J. Interv. Cardiol. 2005, 18:27-31.
121. Hedman M., Muona K., Hedman A., Kivela A., Syvanne M., Eranen J., Rantala A., Stjernvall J., Nieminen M.S., Hartikainen J., Yla-Herttuala S. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther. 2009, 16:629-634.
122. Baumgartner I., Chronos N., Comerota A., Henry T., Pasquet J.P., Finiels F., Caron A., Dedieu J.F., Pilsudski R., Delaere P. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol. Ther. 2009, 17:914-921.
123. Morishita R., Aoki M., Hashiya N., Makino H., Yamasaki K., Azuma J., Sawa Y., Matsuda H., Kaneda Y., Ogihara T. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004, 44:203-209.
124. Gaffney M.M., Hynes S.O., Barry F., O'Brien T. Cardiovascular gene therapy: current status and therapeutic potential. Br. J. Pharmacol. 2007, 152:175-188.
125. Kusumanto Y.H., van Weel V., Mulder N.H., Smit A.J., van den Dungen J.J., Hooymans J.M., Sluiter W.J., Tio R.A., Quax P.H., Gans R.O., Dullaart R.P., Hospers G.A. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum. Gene Ther. 2006, 17:683-691.
126. Powell R.J., Simons M., Mendelsohn F.O., Daniel G., Henry T.D., Koga M., Morishita R., Annex B.H. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008, 118:58-65.
127. Laitinen M., Hartikainen J., Hiltunen M.O., Eranen J., Kiviniemi M., Narvanen O., Makinen K., Manninen H., Syvanne M., Martin J.F., Laakso M., Yla-Herttuala S. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther. 2000, 11:263-270.
128. Hedman M., Hartikainen J., Syvanne M., Stjernvall J., Hedman A., Kivela A., Vanninen E., Mussalo H., Kauppila E., Simula S., Narvanen O., Rantala A., Peuhkurinen K., Nieminen M.S., Laakso M., Yla-Herttuala S. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107:2677-2683.
129. Merdan T., Kopecek J., Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 2002, 54:715-758.
130. Suh W., Han S.O., Yu L., Kim S.W. An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol. Ther. 2002, 6:664-672.
131. Anderson D.G., Lynn D.M., Langer R. Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. Angew. Chem. Int. Ed. Engl. 2003, 42:3153-3158.
132. Lynn D.M., Anderson D.G., Putnam D., Langer R. Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. J. Am. Chem. Soc. 2001, 123:8155-8156.
133. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., Bacallado S.A., Nguyen D.N., Fuller J., Alvarez R., Borodovsky A., Borland T., Constien R., de Fougerolles A., Dorkin J.R., Narayanannair Jayaprakash K., Jayaraman M., John M., Koteliansky V., Manoharan M., Nechev L., Qin J., Racie T., Raitcheva D., Rajeev K.G., Sah D.W., Soutschek J., Toudjarska I., Vornlocher H.P., Zimmermann T.S., Langer R., Anderson D.G. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 2008, 26:561-569.
134. Akinc A., Langer R. Measuring the pH environment of DNA delivered using nonviral vectors: implications for lysosomal trafficking. Biotechnol. Bioeng. 2002, 78:503-508.
135. Green J.J., Shi J., Chiu E., Leshchiner E.S., Langer R., Anderson D.G. Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjug. Chem. 2006, 17:1162-1169.
136. Zugates G.T., Peng W., Zumbuehl A., Jhunjhunwala S., Huang Y.H., Langer R., Sawicki J.A., Anderson D.G. Rapid optimization of gene delivery by parallel end-modification of poly(beta-amino ester)s. Mol. Ther. 2007, 15:1306-1312.
137. Sunshine J., Green J.J., Mahon K.P., Yang F., Eltoukhy A.A., Nguyen D.N., Langer R., Anderson D.G. Small-molecule end-groups of linear polymer determine cell-type gene-delivery efficacy. Adv. Mater. 2009, 21:4947-4951.
138. Anderson D.G., Akinc A., Hossain N., Langer R. Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters). Mol. Ther. 2005, 11:426-434.
139. Anderson D.G., Peng W., Akinc A., Hossain N., Kohn A., Padera R., Langer R., Sawicki J.A. A polymer library approach to suicide gene therapy for cancer. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16028-16033.
140. Huang Y.H., Zugates G.T., Peng W., Holtz D., Dunton C., Green J.J., Hossain N., Chernick M.R., Padera R.F., Langer R., Anderson D.G., Sawicki J.A. Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res. 2009, 69:6184-6191.
141. Green J.J., Zugates G.T., Tedford N.C., Huang Y.H., Griffith L.G., Lauffenburger D.A., Sawicki J.A., Langer R., Anderson D.G. Combinatorial modification of degradable polymers enables transfection of human cells comparable to adenovirus. Adv. Mater. 2007, 19:2836-2842.
142. Yang F., Green J.J., Dinio T., Keung L., Cho S.W., Park H., Langer R., Anderson D.G. Gene delivery to human adult and embryonic cell-derived stem cells using biodegradable nanoparticulate polymeric vectors. Gene Ther. 2009, 16:533-546.
143. Green J.J., Zhou B.Y., Mitalipova M.M., Beard C., Langer R., Jaenisch R., Anderson D.G. Nanoparticles for gene transfer to human embryonic stem cell colonies. Nano Lett. 2008, 8:3126-3130.
144. Yang F., Cho S.W., Son S.M., Bogatyrev S.R., Singh D., Green J.J., Mei Y., Park S., Bhang S.H., Kim B.S., Langer R., Anderson D.G. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3317-3322.
145. Akinc A., Goldberg M., Qin J., Dorkin J.R., Gamba-Vitalo C., Maier M., Jayaprakash K.N., Jayaraman M., Rajeev K.G., Manoharan M., Koteliansky V., Rohl I., Leshchiner E.S., Langer R., Anderson D.G. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 2009, 17:872-879.
146. Frank-Kamenetsky M., Grefhorst A., Anderson N.N., Racie T.S., Bramlage B., Akinc A., Butler D., Charisse K., Dorkin R., Fan Y., Gamba-Vitalo C., Hadwiger P., Jayaraman M., John M., Jayaprakash K.N., Maier M., Nechev L., Rajeev K.G., Read T., Rohl I., Soutschek J., Tan P., Wong J., Wang G., Zimmermann T., de Fougerolles A., Vornlocher H.P., Langer R., Anderson D.G., Manoharan M., Koteliansky V., Horton J.D., Fitzgerald K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11915-11920.
147. Huang Y.H., Bao Y., Peng W., Goldberg M., Love K., Bumcrot D.A., Cole G., Langer R., Anderson D.G., Sawicki J.A. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3426-3430.
148. Cho S.W., Goldberg M., Son S.M., Xu Q.B., Yang F., Mei Y., Bogatyrev S., Langer R., Anderson D.G. Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells. Adv. Funct. Mater. 2009, 19:3112-3118.
149. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
150. Anand S., Majeti B.K., Acevedo L.M., Murphy E.A., Mukthavaram R., Scheppke L., Huang M., Shields D.J., Lindquist J.N., Lapinski P.E., King P.D., Weis S.M., Cheresh D.A. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat. Med. 2010, 16:909-914.